RUNX3 and cancer: We find that top ranking biomarkers for the explanation of treatment effect variation are enriched in multiple cancer related pathways (Figure 7A), including the intrinsic pathway for apoptosis (R-HSA-109606, P = 2.86 × 10−14), Signaling by Interleukins (R-HSA-449147, P = 2.86 × 10−14), Programmed Cell Death (R-HSA-5357801, P = 9.7 × 10−11), PIP3 activates AKT signaling (R-HSA-1257604, P = 2.98 × 10−8), RUNX3 regulates WNT signaling (R-HSA-8951430, P = 1.03 × 10−5), and RNA Polymerase II Transcription (R-HSA-73857, P = 9.4 × 10−5).